Clinical Features and Treatment of GEP NETs in a Spanish Hospital Through 8 Years Abstract #639

Introduction: There are discrepancies in Gastroenteropancreatic NETs (GEPNET) incidence, characteristics and patterns of care among institutional registries and countries.
Aim(s): To analyze the epidemiology and treatment of GEPNETs in a reference hospital for Asturias, a Spanish region of 1 million inhabitants.
Materials and methods: Retrospective analysis of 217 patients (median age 66, 57% males) with metastatic GEPNET attended in a Medical Oncology Department from 2005 to 2012. Data was obtained from the National Cancer Registry for GEPNETs (RGETNE) launched by the Spanish Scientific Society of NETs (GETNE).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Msc MD María del Pilar Solis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Josephine Schenk